AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11194409 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) study examining brain activity during verbal discrimination learning
Number of subjects: 16
Study 11194409 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-trial verbal discrimination learning task
Number of subjects: 16
Study 9489439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiluminescence (CL) response of PMNLs to chemotactic peptide FMLP
Number of subjects: 48
Study 9489439 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy blood donors)
Number of subjects: 48
Study 8397489 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg once daily, administered either as a single dose or repeated for 2 to 6 days.
Number of subjects: 0
Study 3491794 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg fluproquazone
Number of subjects: 0
Study 3491794 — intervention group
Group type: COMPARATOR
Intervention: 500 mg paracetamol
Number of subjects: 0
Study 29492612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA (two doses of 20 mg/kg)
Number of subjects: 120
Study 29492612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (two doses of 15 mg/kg)
Number of subjects: 120
Study 29492612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 120
Study 29492612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA
Number of subjects: 120
Study 29492612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA
Number of subjects: 120
Study 29492612 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 27567675 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpreserved latanoprost eye drops (UNL)
Number of subjects: 183
Study 27567675 — intervention group
Group type: COMPARATOR
Intervention: Preserved latanoprost eye drops (LBAK)
Number of subjects: 183
Study 25379438 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (MLN)
Number of subjects: 15
Study 25379438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22088201 — intervention group
Group type: EXPERIMENTAL
Intervention: Painless STEMI
Number of subjects: 763
Study 22088201 — intervention group
Group type: COMPARATOR
Intervention: Painful STEMI
Number of subjects: 763
Study 20733096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan (10 mg)
Number of subjects: 47
Study 20733096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 18275882 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 4
Study 18275882 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC)
Number of subjects: 4
Study 17187087 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic follow-up (Group B)
Number of subjects: 17
Study 17187087 — intervention group
Group type: COMPARATOR
Intervention: Observational follow-up (Group A)
Number of subjects: 17
Study 11979505 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium (500 mg day(‐1)) + calcitonin (nasal spray 100 U day(‐1))
Number of subjects: 30
Study 11979505 — intervention group
Group type: COMPARATOR
Intervention: calcium only
Number of subjects: 30
Study 10228617 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 159
Study 10228617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 7867354 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 7867354 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 1789813 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S)
Number of subjects: 48
Study 1789813 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (S) + Cholestyramine (C)
Number of subjects: 48
Study 7149969 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 25 mg
Number of subjects: 15
Study 7149969 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 50 mg
Number of subjects: 15
Study 7149969 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 100 mg
Number of subjects: 15
Study 7149969 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 250 mg
Number of subjects: 15
Study 7149969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7149969 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (general)
Number of subjects: 15
Study 29802136 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal suction
Number of subjects: 24
Study 29802136 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal swab
Number of subjects: 24
Study 30375324 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage plus advice
Number of subjects: 189
Study 30375324 — intervention group
Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 189
Study 27525365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 136
Study 24528648 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukodepleted RBC transfusion
Number of subjects: 20
Study 24528648 — intervention group
Group type: COMPARATOR
Intervention: Non-leukodepleted RBC transfusion
Number of subjects: 20
Study 21703724 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) at a frequency of 6 Hz for 5 consecutive days, daily series of 5 periods of 1 minute
Number of subjects: 34
Study 21703724 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 34
Study 20363809 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention
Number of subjects: 145
Study 20363809 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 145
Study 18053384 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of endometriosis
Number of subjects: 100
Study 18053384 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 100
Study 16075779 — intervention group
Group type: COMPARATOR
Intervention: Fixed Repetition (FR)
Number of subjects: 60
Study 16075779 — intervention group
Group type: COMPARATOR
Intervention: Periodised (PER)
Number of subjects: 60
Study 16075779 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (C)
Number of subjects: 60
Study 12118758 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic minitracheostomy insertion with regular aspiration
Number of subjects: 102
Study 12118758 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative respiratory therapy
Number of subjects: 102
Study 9752429 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally preperitoneal (TPP) approach
Number of subjects: 461
Study 9752429 — intervention group
Group type: COMPARATOR
Intervention: Shouldice procedure
Number of subjects: 461
Study 9752429 — intervention group
Group type: COMPARATOR
Intervention: Stoppa procedure
Number of subjects: 461
Study 7915237 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study 7915237 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol
Number of subjects: 20
Study 3135167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g
Number of subjects: 30
Study 3135167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 2g
Number of subjects: 30
Study 3135167 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 28755409 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1193 (0.05 to 0.6 mg/kg)
Number of subjects: 56
Study 28755409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 28755409 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1193 (0.6 mg/kg)
Number of subjects: 56
Study 28755409 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1193 (all doses)
Number of subjects: 56
Study 27154359 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (800mg/day)
Number of subjects: 0
Study 25570401 — intervention group
Group type: EXPERIMENTAL
Intervention: User-driven treadmill control (active walking)
Number of subjects: 9
Study 25570401 — intervention group
Group type: COMPARATOR
Intervention: Normal treadmill (passive walking)
Number of subjects: 9
Study 22850268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (mean dose=17 mg/day)
Number of subjects: 389
Study 22850268 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (mean dose=16 mg/day)
Number of subjects: 389
Study 22850268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 389
Study 22850268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole and Olanzapine
Number of subjects: 389
Study 20470069 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a canine abdominal model (n = 15)
Number of subjects: 33
Study 20470069 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 33
Study 20470069 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced group (n = 8)
Number of subjects: 33
Study 18496508 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 860
Study 18496508 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 860
Study 15717192 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 607
Study 15717192 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 607
Study 15717192 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Number of subjects: 607
Study 15223075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa drink (HFCD; 187 mg flavan-3-ols/100 ml)
Number of subjects: 20
Study 15223075 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol cocoa drink (LFCD; 14 mg/100 ml)
Number of subjects: 20
Study 15223075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa drink (HFCD) with physical exercise
Number of subjects: 20
Study 10737434 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 subtype B variants (GPGR, GWGR, GFGR, GPGS)
Number of subjects: 35
Study 10737434 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralization by autologous sera
Number of subjects: 35
Study 10737434 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide ELISA seroreactivity
Number of subjects: 35
Study 9285502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of alpha-lipoic acid (ALA) 1,200 mg
Number of subjects: 328
Study 9285502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of alpha-lipoic acid (ALA) 600 mg
Number of subjects: 328
Study 9285502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamburg Pain Adjective List (HPAL) total scale with ALA 1,200 mg
Number of subjects: 328
Study 9285502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamburg Pain Adjective List (HPAL) total scale with ALA 600 mg
Number of subjects: 328
Study 9285502 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral dose of alpha-lipoic acid (ALA) 800 mg
Number of subjects: 328
Study 9285502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 328
Study 8099380 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy
Number of subjects: 47
Study 8099380 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion acquisition
Number of subjects: 47
Study 3522558 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 12
Study 3522558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2573761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake of 100 mmol per day
Number of subjects: 20
Study 2573761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake of 50 mmol per day
Number of subjects: 20
Study 2573761 — intervention group
Group type: COMPARATOR
Intervention: Sodium intake of 200 mmol per day
Number of subjects: 20
Study 2573761 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt restriction for a further year
Number of subjects: 20
Study 30203031 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand-name label (n = 51)
Number of subjects: 101
Study 30203031 — intervention group
Group type: COMPARATOR
Intervention: Generic label (n = 50)
Number of subjects: 101
Study 28376409 — intervention group
Group type: EXPERIMENTAL
Intervention: Mem‐ECT
Number of subjects: 59
Study 28376409 — intervention group
Group type: COMPARATOR
Intervention: Active control (nonspecific mental stimulation)
Number of subjects: 59
Study 28376409 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 59
Study 24585072 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting Sibling Bonds (PSB) intervention (n=13)
Number of subjects: 22
Study 24585072 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n=9)
Number of subjects: 22
Study 23347721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized naloxone (2 mg in 3 mL normal saline)
Number of subjects: 73
Study 21309842 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 658
Study 21309842 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 658
Study 21309842 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 658
Study 19424051 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/LPV/r
Number of subjects: 50
Study 19424051 — intervention group
Group type: COMPARATOR
Intervention: NVP/LPV/r
Number of subjects: 50
Study 17074116 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate poisoning group
Number of subjects: 97
Study 17074116 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe poisoning group
Number of subjects: 97
Study 17074116 — intervention group
Group type: EXPERIMENTAL
Intervention: Death group
Number of subjects: 97
Study 17074116 — intervention group
Group type: COMPARATOR
Intervention: Survival group
Number of subjects: 97
Study 17074116 — intervention group
Group type: COMPARATOR
Intervention: Mild poisoning group
Number of subjects: 97
Study 15671203 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF3381 (100, 200, and 400 mg twice daily for 2 weeks)
Number of subjects: 36
Study 11595608 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 80
Study 11595608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9386688 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade blood cardioplegia (group 1)
Number of subjects: 224
Study 9386688 — intervention group
Group type: COMPARATOR
Intervention: Retrograde blood cardioplegia (group 2)
Number of subjects: 224
Study 7525162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 47
Study 7525162 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 47
Study 2956296 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (various dosage schedules)
Number of subjects: 72
Study 29771211 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months)
Number of subjects: 1428
Study 29771211 — intervention group
Group type: COMPARATOR
Intervention: Long-term anticoagulation (12 months)
Number of subjects: 1428
Study 27956009 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance varenicline
Number of subjects: 0
Study 27956009 — intervention group
Group type: COMPARATOR
Intervention: Maintenance placebo
Number of subjects: 0
Study 26226248 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCM (long umbilical cord and milking)
Number of subjects: 200
Study 26226248 — intervention group
Group type: COMPARATOR
Intervention: Control (cord clamped at 5 cm and not milked)
Number of subjects: 200
Study 26226248 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCM
Number of subjects: 200
Study 26226248 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 23706887 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Our Solutions and Connections (BOSC) intervention
Number of subjects: 61
Study 23706887 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 61
Study 21364739 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants from Northern Ireland
Number of subjects: 0
Study 21364739 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants from Serbia
Number of subjects: 0
Study 21364739 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants from Guatemala
Number of subjects: 0
Study 21364739 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants from Peru
Number of subjects: 0
Study 21364739 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized additive mixed models
Number of subjects: 0
Study 21364739 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cross-cultural ratings
Number of subjects: 0
Study 18191057 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 4 weeks
Number of subjects: 32
Study 18191057 — intervention group
Group type: COMPARATOR
Intervention: Control group received a booklet with basic education for metabolic syndrome
Number of subjects: 32
Study 18191057 — intervention group
Group type: EXPERIMENTAL
Intervention: TLM intervention
Number of subjects: 32
Study 18191057 — intervention group
Group type: COMPARATOR
Intervention: Both groups post-intervention
Number of subjects: 32
Study 16818832 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselor intervention (weekly for 6 weeks)
Number of subjects: 108
Study 16818832 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 108
Study 14615626 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (PET1 to PET2)
Number of subjects: 14
Study 14615626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasic patients (PET1 to PET2)
Number of subjects: 14
Study 11081343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis therapy
Number of subjects: 39
Study 11081343 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 39
Study 11081343 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis
Number of subjects: 39
Study 8869630 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenage Mothers‐Grandmothers Program
Number of subjects: 65
Study 1844997 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate, noncarbonated drink
Number of subjects: 4
Study 1844997 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate, carbonated drink
Number of subjects: 4
Study 1844997 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate, noncarbonated drink
Number of subjects: 4
Study 1844997 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate, carbonated drink
Number of subjects: 4
Study 1844997 — intervention group
Group type: EXPERIMENTAL
Intervention: All beverages (ad libitum drinking)
Number of subjects: 4
Study 1844997 — intervention group
Group type: EXPERIMENTAL
Intervention: All beverages (sweat rate, body weight loss, fluid replacement)
Number of subjects: 4
Study 1844997 — intervention group
Group type: EXPERIMENTAL
Intervention: All beverages (heart rate, rectal temperature, perceived exertion)
Number of subjects: 4
Study 6190881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study 6190881 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus nasal swabs from patients and operating staff
Number of subjects: 0
Study 31122968 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) applied to the skeletal muscle of the entire lower extremity for 5 weeks, three times/week for 30-40 min during haemodialysis.
Number of subjects: 20
Study 31122968 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 20
Study 30632329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% bio-adhesive chlorhexidine gel
Number of subjects: 180
Study 30632329 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 180
Study 26849799 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation at 400 mg per day
Number of subjects: 23
Study 26849799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24436138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit4Life (tailored weight management intervention)
Number of subjects: 38
Study 24436138 — intervention group
Group type: COMPARATOR
Intervention: Control (generic weight management intervention)
Number of subjects: 38
Study 22466947 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-needling (DN group)
Number of subjects: 65
Study 22466947 — intervention group
Group type: COMPARATOR
Intervention: Superficial-needling (SN group)
Number of subjects: 65
Study 20386121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint condition (10 shots with sprints between attempts)
Number of subjects: 11
Study 20386121 — intervention group
Group type: COMPARATOR
Intervention: Control condition (10 shots with 35-second rest)
Number of subjects: 11
Study 18567081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) suppository
Number of subjects: 60
Study 18567081 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 15778427 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (800/200 mg qd or 400/100 mg bid)
Number of subjects: 35
Study 15778427 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine
Number of subjects: 35
Study 15778427 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 35
Study 12028208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with calcium alginate dressings (UrgoSorb) for 4 weeks followed by hydrocolloid dressings (Algoplaque) for 4 weeks
Number of subjects: 110
Study 12028208 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressings (DuodermE) for 8 weeks
Number of subjects: 110
Study 10375362 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortified preterm formula (0.9 mg/dl iron)
Number of subjects: 78
Study 10375362 — intervention group
Group type: COMPARATOR
Intervention: Fortified term formula (0.5 mg/dl iron)
Number of subjects: 78